File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Misoprostol with or without letrozole pretreatment for termination of pregnancy: A randomized controlled trial

TitleMisoprostol with or without letrozole pretreatment for termination of pregnancy: A randomized controlled trial
Authors
KeywordsEstradiol
Letrozole
Misoprostol
Placebo
Progesterone
Issue Date2011
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.greenjournal.org
Citation
Obstetrics And Gynecology, 2011, v. 117 n. 2 PART 1, p. 317-323 How to Cite?
AbstractObjective: To compare the success rate and side effects of letrozole and misoprostol versus misoprostol alone for medical termination of early pregnancy. Methods: Patients requesting termination of pregnancy up to 63 days of gestation were randomized into two groups. The letrozole group received letrozole 10 mg daily for 3 days followed by 800 micrograms of vaginal misoprostol, while the placebo group received placebo for 3 days followed by the same dosage of misoprostol. The complete abortion rate and the side effects profiles of the two groups were compared. The primary outcome measure was the complete abortion rate. Results: A total of 168 women were recruited. The complete abortion rate of the letrozole group was significantly higher than that of the placebo group (86.9% compared with 72.6%, relative risk [RR] 1.20, 95% confidence interval [CI] 1.03-1.40). The complete abortion rate in gestations up to 49 days was significantly higher in the letrozole group than in the placebo group (93.3% compared with 78.7%, RR 1.19, 95% CI 1.002-1.40), while the corresponding rates for gestation between 50 and 63 days were not significantly different between the two groups. There were significantly fewer women complaining of vomiting in the letrozole group than those in the placebo group (8.3% compared with 19.0%, P=.043, RR 2.29, 95% CI 1.005-5.27). Conclusion: The use of letrozole and misoprostol is associated with a higher complete abortion rate. Clinical Trial Registration:: HKClinicalTrials.com, http://www. hkclinicaltrials.com, HKCTR-349. © 2011 by The American College of Obstetricians and Gynecologists. Published by Lippincott Williams & Wilkins.
Persistent Identifierhttp://hdl.handle.net/10722/139908
ISSN
2015 Impact Factor: 5.656
2015 SCImago Journal Rankings: 2.899
ISI Accession Number ID
Funding AgencyGrant Number
Research Grants Council of Hong KongHKU 765508M
Funding Information:

Supported by General Research Fund of the Research Grants Council of Hong Kong (HKU 765508M).

References
Grants

 

DC FieldValueLanguage
dc.contributor.authorLee, VCYen_HK
dc.contributor.authorNg, EHYen_HK
dc.contributor.authorYeung, WSBen_HK
dc.contributor.authorHo, PCen_HK
dc.date.accessioned2011-09-23T06:00:10Z-
dc.date.available2011-09-23T06:00:10Z-
dc.date.issued2011en_HK
dc.identifier.citationObstetrics And Gynecology, 2011, v. 117 n. 2 PART 1, p. 317-323en_HK
dc.identifier.issn0029-7844en_HK
dc.identifier.urihttp://hdl.handle.net/10722/139908-
dc.description.abstractObjective: To compare the success rate and side effects of letrozole and misoprostol versus misoprostol alone for medical termination of early pregnancy. Methods: Patients requesting termination of pregnancy up to 63 days of gestation were randomized into two groups. The letrozole group received letrozole 10 mg daily for 3 days followed by 800 micrograms of vaginal misoprostol, while the placebo group received placebo for 3 days followed by the same dosage of misoprostol. The complete abortion rate and the side effects profiles of the two groups were compared. The primary outcome measure was the complete abortion rate. Results: A total of 168 women were recruited. The complete abortion rate of the letrozole group was significantly higher than that of the placebo group (86.9% compared with 72.6%, relative risk [RR] 1.20, 95% confidence interval [CI] 1.03-1.40). The complete abortion rate in gestations up to 49 days was significantly higher in the letrozole group than in the placebo group (93.3% compared with 78.7%, RR 1.19, 95% CI 1.002-1.40), while the corresponding rates for gestation between 50 and 63 days were not significantly different between the two groups. There were significantly fewer women complaining of vomiting in the letrozole group than those in the placebo group (8.3% compared with 19.0%, P=.043, RR 2.29, 95% CI 1.005-5.27). Conclusion: The use of letrozole and misoprostol is associated with a higher complete abortion rate. Clinical Trial Registration:: HKClinicalTrials.com, http://www. hkclinicaltrials.com, HKCTR-349. © 2011 by The American College of Obstetricians and Gynecologists. Published by Lippincott Williams & Wilkins.en_HK
dc.languageengen_US
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.greenjournal.orgen_HK
dc.relation.ispartofObstetrics and Gynecologyen_HK
dc.subjectEstradiol-
dc.subjectLetrozole-
dc.subjectMisoprostol-
dc.subjectPlacebo-
dc.subjectProgesterone-
dc.titleMisoprostol with or without letrozole pretreatment for termination of pregnancy: A randomized controlled trialen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0029-7844&volume=117&issue=2 pt. 1&spage=317&epage=323&date=2011&atitle=Misoprostol+with+or+without+letrozole+pretreatment+for+termination+of+pregnancy:+a+randomized+controlled+trial-
dc.identifier.emailNg, EHY:nghye@hkucc.hku.hken_HK
dc.identifier.emailYeung, WSB:wsbyeung@hkucc.hku.hken_HK
dc.identifier.emailHo, PC:pcho@hku.hken_HK
dc.identifier.authorityNg, EHY=rp00426en_HK
dc.identifier.authorityYeung, WSB=rp00331en_HK
dc.identifier.authorityHo, PC=rp00325en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1097/AOG.0b013e3182073fbfen_HK
dc.identifier.pmid21252745-
dc.identifier.scopuseid_2-s2.0-79251546433en_HK
dc.identifier.hkuros196579en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-79251546433&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume117en_HK
dc.identifier.issue2 PART 1en_HK
dc.identifier.spage317en_HK
dc.identifier.epage323en_HK
dc.identifier.eissn1873-233X-
dc.identifier.isiWOS:000286460600017-
dc.publisher.placeUnited Statesen_HK
dc.relation.projectCombined use of letrozole and misoprostol for medical termination of pregnancy-
dc.identifier.scopusauthoridLee, VCY=35758969300en_HK
dc.identifier.scopusauthoridNg, EHY=35238184300en_HK
dc.identifier.scopusauthoridYeung, WSB=7102370745en_HK
dc.identifier.scopusauthoridHo, PC=7402211440en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats